Cargando…

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer

Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been significant efforts to identify biomarkers that can predict response and toxicities related to immune checkpoint inhibitor (ICPI) therapy. Despite these advances, it has been challenging to tease out why a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naqash, Abdul Rafeh, Kihn-Alarcón, Alba J., Stavraka, Chara, Kerrigan, Kathleen, Maleki Vareki, Saman, Pinato, David James, Puri, Sonam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Cancer Immunotherapy: Recent Advances and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267312/ https://www.ncbi.nlm.nih.gov/pubmed/34277834 http://dx.doi.org/10.21037/atm-20-6427

Ejemplares similares

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
por: Florou, Vaia, et al.
Publicado: (2021)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
por: Narkhede, Mayur, et al.
Publicado: (2021)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)

The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
por: Marinelli, Brett, et al.
Publicado: (2022)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
por: Deluce, Jasna, et al.
Publicado: (2022)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management
por: Leung, T.F, et al.
Publicado: (2003)

Applications of dual energy CT in clinical practice: A pictorial essay
por: Sanghavi, Parang S, et al.
Publicado: (2019)

MR-guided focused ultrasound surgery: A novel non-invasive technique in the treatment of adenomyosis –18 month's follow-up of 12 cases
por: Dev, Bhawna, et al.
Publicado: (2019)

Mechanisms of rhinovirus-induced asthma
por: Papadopoulos, Nikolaos G, et al.
Publicado: (2004)

Role of the microbiome in human development
por: Dominguez-Bello, Maria Gloria, et al.
Publicado: (2019)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

Interaction between drugs and the gut microbiome
por: Weersma, Rinse K, et al.
Publicado: (2020)

Gut microbiome and health: mechanistic insights
por: de Vos, Willem M, et al.
Publicado: (2022)

Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors
por: Hoover, Ashley R, et al.
Publicado: (2022)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Human gut microbiome: hopes, threats and promises
por: Cani, Patrice D
Publicado: (2018)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_84ppvjjedsm4i6c7i42pulfqld